Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

Results

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT03522246IIINewly diagnosed stage III/IV ovarian cancer that responded to first-line platinum therapyATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)AZ, CA, CO, CT, FL, GA, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MO, NV, NJ, NY, NC, OH, OK, OR, PA, SD, TX, UT, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitorApproved in Ovarian Cancer
NCT03735589I/IINewly diagnosed stage II-IV ovarian cancer that responded to first-line platinum therapyA Phase I/IIa Safety and Immunologic Efficacy Trial of Intraperitoneal Induction of CTLs Combined With Alpha-Dendritic Cell Vaccine for Primary Ovarian CancerNYView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Alpha-DC1 vaccineImmune response against tumor-associated antigensClinical Trials
Autologous nCTLsAutologous Natural Killer Cell-like nCTLs, autologous natural killer-like cytotoxic lymphocytes, autologous aDC1-induced CTLsAnti-tumor immune responseClinical Trials
NCT03839524IHigh grade serous ovarian cancer with complete response after first-line platinum therapy (w/ banked tumor tissue)A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.AZ, FL, MNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TG4050Modified Vaccinia Ankara (MVA) personlized vaccine, MyVACImmune response against tumor-associated antigensClinical Trials
NCT03054909IStage III/IV ovarian cancer with stable disease or better after first-line IV/IP cisplatin and paclitaxel therapy (maintenance)QUILT-2.021: Randomized Study of Single Course of Intraperitoneal (IP) ALT-803 Followed by Subcutaneous (SQ) Maintenance ALT-803 Versus Subcutaneous (SQ) Maintenance ALT-803 Only After 1st Line Chemotherapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal CancerMNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
ALT-803IL-2/IL-15 receptor beta-common gamma chain agonistClinical Trials

If you have any questions or would like help with your search, please call us at: 858-264-5124 or email us at patientsupport@clearityfoundation.org.